Compare Stocks → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:BKDNASDAQ:CARANASDAQ:GHRSNASDAQ:TSVT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBKDBrookdale Senior Living$6.81+0.9%$6.23$3.33▼$7.05$1.29B1.321.82 million shs158,054 shsCARACara Therapeutics$0.68+0.9%$0.83$0.50▼$4.67$37.03M0.7640,193 shs44,326 shsGHRSGH Research$10.72-3.2%$9.92$5.05▼$14.64$557.76M0.84131,660 shs10,076 shsTSVT2seventy bio$3.71-13.1%$5.11$1.53▼$12.69$190.36M1.841.36 million shs791,725 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBKDBrookdale Senior Living-2.46%+4.49%+4.33%+17.80%+59.95%CARACara Therapeutics-5.02%-8.24%-18.09%+18.95%-82.91%GHRSGH Research-1.95%+0.82%+5.02%+61.05%+40.25%TSVT2seventy bio-7.78%-15.61%-12.86%+29.79%-50.23%The "Smart Money" Is Ready for May 1st Are You? (Ad)Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBKDBrookdale Senior Living3.2459 of 5 stars2.32.00.04.92.41.70.6CARACara Therapeutics3.9579 of 5 stars3.42.00.04.21.91.71.3GHRSGH Research1.4524 of 5 stars3.51.00.00.02.32.50.0TSVT2seventy bio3.4943 of 5 stars4.21.00.00.03.33.31.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBKDBrookdale Senior Living2.50Moderate Buy$7.5010.13% UpsideCARACara Therapeutics2.75Moderate Buy$9.751,339.33% UpsideGHRSGH Research3.00Buy$39.50268.47% UpsideTSVT2seventy bio2.38Hold$13.17254.90% UpsideCurrent Analyst RatingsLatest BKD, CARA, GHRS, and TSVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/9/2024BKDBrookdale Senior LivingRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/8/2024TSVT2seventy bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $12.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024TSVT2seventy bioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/4/2024GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/1/2024GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $39.001/31/2024TSVT2seventy bioLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform1/31/2024TSVT2seventy bioTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBKDBrookdale Senior Living$3.02B0.43$0.84 per share8.12$2.15 per share3.17CARACara Therapeutics$20.97M1.77N/AN/A$1.05 per share0.65GHRSGH ResearchN/AN/AN/AN/A$4.94 per shareN/ATSVT2seventy bio$100.39M1.90N/AN/A$5.04 per share0.74Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBKDBrookdale Senior Living-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/7/2024 (Confirmed)CARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)GHRSGH Research-$35.59M-$0.68N/AN/AN/AN/A-15.48%-15.01%5/9/2024 (Estimated)TSVT2seventy bio-$217.57M-$4.42N/A53.00N/A-216.73%-59.19%-29.67%5/1/2024 (Estimated)Latest BKD, CARA, GHRS, and TSVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/ABKDBrookdale Senior Living-$0.17N/A+$0.17N/AN/AN/A 3/5/202412/31/2023TSVT2seventy bio-$1.22-$1.11+$0.11-$1.11$13.91 million$10.68 million 3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/29/2024Q4 2023GHRSGH Research-$0.20-$0.21-$0.01-$0.21N/AN/A2/20/2024Q4 2023BKDBrookdale Senior Living-$0.19-$0.40-$0.21-$0.40N/A$754.48 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBKDBrookdale Senior LivingN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBKDBrookdale Senior Living9.400.800.80CARACara TherapeuticsN/A4.544.43GHRSGH ResearchN/A24.4924.49TSVT2seventy bioN/A3.983.98OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBKDBrookdale Senior LivingN/ACARACara Therapeutics44.66%GHRSGH Research56.90%TSVT2seventy bio93.90%Insider OwnershipCompanyInsider OwnershipBKDBrookdale Senior Living1.50%CARACara Therapeutics4.20%GHRSGH Research41.60%TSVT2seventy bio2.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBKDBrookdale Senior Living25,200189.34 million186.50 millionOptionableCARACara Therapeutics5554.67 million52.36 millionOptionableGHRSGH Research4952.03 million30.38 millionOptionableTSVT2seventy bio27451.31 million49.98 millionOptionableBKD, CARA, GHRS, and TSVT HeadlinesSourceHeadline2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?zacks.com - April 24 at 11:07 AM2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Whymsn.com - April 17 at 1:11 PM2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Whyzacks.com - April 17 at 12:05 PM2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Up 29.7% in Marchamericanbankingnews.com - April 15 at 2:50 AM2seventy bio Inc Ordinary Sharesmorningstar.com - April 13 at 9:15 AMCiti raises 2Seventy Bio stock target on FDA approvalinvesting.com - April 10 at 11:37 PMAnalysts Offer Predictions for 2seventy bio, Inc.'s Q1 2024 Earnings (NASDAQ:TSVT)marketbeat.com - April 10 at 8:12 AMLeerink Partnrs Analysts Raise Earnings Estimates for 2seventy bio, Inc. (NASDAQ:TSVT)marketbeat.com - April 9 at 6:25 AMPositive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamicsmarkets.businessinsider.com - April 8 at 7:36 PM2seventy bio (NASDAQ:TSVT) Price Target Raised to $12.00marketbeat.com - April 8 at 7:29 PMBuy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic Outlookmarkets.businessinsider.com - April 7 at 7:49 PMBristol Myers Wins FDA Nod for Abecmamsn.com - April 5 at 4:27 PMFDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancermsn.com - April 5 at 4:27 PMBristol Myers, 2seventy bio's Abecma approved for earlier line multiple myelomaseekingalpha.com - April 5 at 4:27 PMU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapyfinance.yahoo.com - April 5 at 9:35 AM2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of "Hold" from Brokeragesmarketbeat.com - April 4 at 2:15 AMInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Buys 300,000 Shares of Stockinsidertrades.com - March 26 at 4:18 AMInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Acquires 300,000 Shares of Stockmarketbeat.com - March 25 at 11:49 PM2seventy bio appoints Eli Casdin and Charles Newton to its board of directorsmsn.com - March 20 at 6:07 PM2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directorsbusinesswire.com - March 20 at 5:04 PMThinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?morningstar.com - March 20 at 1:07 PMContineum Therapeutics files for IPOstatnews.com - March 18 at 10:13 AMBristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approvalmarketwatch.com - March 17 at 10:41 AMPositive FDA AdCom votes for cell therapies Abecma and Carvyktithepharmaletter.com - March 16 at 6:42 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrookdale Senior LivingNYSE:BKDBrookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.Cara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.GH ResearchNASDAQ:GHRSGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.2seventy bioNASDAQ:TSVT2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.